Coya Therapeutics (COYA) EBITDA Margin (2023 - 2026)
Coya Therapeutics (COYA) posted EBITDA Margin of 3042.13% for Q1 2026, down 1897.52% sequentially from 152.3% in Q4 2025, and down 6524.0% YoY from 47.36% in Q1 2025.
Coya Therapeutics (COYA) EBITDA Margin (2023 - 2026) Analysis & Trends
Coya Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 3042.13% in Q1 2026.
- Quarterly EBITDA Margin fell 6524.0% year-over-year to 3042.13% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 283.64% (up 24398.0% YoY) and the FY2025 annual result came in at 283.87%, up 20149.0% from the prior year.
- EBITDA Margin fell to 3042.13% in Q1 2026 per COYA's latest filing, from 152.3% in the prior quarter.
- Over five years, EBITDA Margin peaked at 30.24% in Q4 2023 and troughed at 209031.51% in Q4 2024.
- A 4-year average of 24842.07% and a median of 2976.89% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin tumbled 20906175 bps in 2024, then surged 20887921 bps in 2025.
- Over 4 years, EBITDA Margin stood at 30.24% in 2023, then slumped by 691308 bps to 209031.51% in 2024, then jumped by 100 bps to 152.3% in 2025, then slumped by 1898 bps to 3042.13% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 3042.13%, 152.3%, and 68.26% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -2,889.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,891.13% |
| Mar 31, 2026 | -3,042.13% |
| Dec 31, 2025 | -152.30% |
| Sep 30, 2025 | -68.26% |
| Jun 30, 2025 | -3,920.47% |
| Mar 31, 2025 | -2,976.89% |
| Dec 31, 2024 | -209,031.51% |
| Jun 30, 2024 | -94.48% |
| Mar 31, 2024 | -4,322.84% |
| Dec 31, 2023 | 30.24% |